Why Regulatory Affairs Training Matters More Than Ever in 2026
Let’s be honest, the FDA does not mess around. With the U.S. Food and Drug Administration enforcing one of the most complex regulatory frameworks on the planet, staying compliant is not just a nice-to-have, it is the difference between bringing a life-saving drug to market and watching your submission gather dust.
The US regulatory landscape is built on the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, with everything codified in Title 21 of the Code of Federal Regulations (21 CFR). For regulatory professionals, that means mastering the full drug development lifecycle from INDs to NDAs, BLAs, and ANDAs, while keeping pace with ICH guidelines for global harmonization.
Whether you are in regulatory affairs, clinical operations, R&D, or quality assurance, one thing is certain, documented and role-appropriate training is not optional. It is expected. And when the FDA comes knocking for an inspection, you had better have your training records in order.
What Makes FDA Compliance So Demanding?
The FDA’s regulatory framework is notoriously rigorous. Here is what US professionals are up against. The Federal Food, Drug, and Cosmetic Act provides the statutory authority for drug regulation. The regulations are codified in 21 CFR Parts 200-499 and 600-699 covering drugs, biologics, and devices. For clinical research, 21 CFR Part 312 governs Investigational New Drug Applications. For marketing approval, 21 CFR Part 314 covers New Drug Applications and 21 CFR Part 601 addresses Biologics License Applications. Additionally, ICH Guidelines across the E, M, Q, and S series provide the framework for international harmonisation of submissions.
Each of these frameworks demands specialized knowledge. And with the FDA’s REdI Conference 2026 and other training events happening throughout the year, the message is clear, continuous learning is non-negotiable.
Our FDA-Aligned Regulatory Affairs Training Courses
At GxP Trainings, we have designed our regulatory affairs training specifically for US professionals who need to stay ahead of the curve. All courses are self-paced, fully online, and include 21 CFR Part 11 compliant certificates with verifiable IDs. These are accepted as documented training records during FDA inspections.
ANDA Compliance and Regulatory Training (Most Relevant for USA)
Price: $499.00
This comprehensive training is essential for the US generic drug industry. It provides an in-depth understanding of preparing and submitting Abbreviated New Drug Applications (ANDAs) to the FDA, incorporating the latest developments under GDUFA III. You will master the Hatch-Waxman Act, bioequivalence science, patent certification under Paragraph IV, and post-approval changes.
This course is designed for Regulatory Affairs Professionals, Generic Drug Developers, Formulation Scientists, and QA/QC Managers. You can access the full course details through this link: ANDA Compliance and Regulatory Training.
Biologics License Application (BLA) Certification Program (Most Relevant for USA)
Price: $499.00
The US biotech sector is booming, and this program is your ticket in. You will gain comprehensive knowledge of planning, preparing, submitting, and reviewing BLAs to the FDA, covering the full eCTD structure, CMC, nonclinical and clinical data, FDA review processes, and inspection readiness.
This program is ideal for Regulatory Affairs Professionals, CMC Scientists, Biotechnology Executives, and Manufacturing Personnel. Explore the program here: Biologics License Application Certification Program.
Mastering the NDA (Most Relevant for USA)
Price: $499.00
Foundational for any US pharmaceutical professional involved in innovative drug development. This course covers the entire drug development and approval process, with a deep dive into each component of the New Drug Application organized into the five CTD modules.
This course is suited for Regulatory Affairs Specialists, Medical Writers, CMC Associates, and Clinical Research Teams. Learn more at: Mastering the NDA.
Mastering the Orphan Drug NDA (Highly Relevant for USA)
Price: $499.00
Learn the step-by-step process for obtaining orphan drug designation from the FDA Office of Orphan Products Development under the Orphan Drug Act of 1983. You will understand the benefits, including seven-year exclusivity and tax credits.
This course is designed for Regulatory Affairs Specialists, Clinical Research Associates, Medical Writers, and Biotech Executives. Access the course here: Mastering the Orphan Drug NDA.
The Investigational New Drug (IND) Framework (Highly Relevant for USA)
Price: $499.00
Critical for anyone involved in initiating clinical trials in the US. This program covers the legal basis for the IND exemption, detailed preparation of the initial IND package, the 30-day review timeline, and safety monitoring.
This course targets Clinical Research Associates, Regulatory Affairs Specialists, Principal Investigators, and Sponsor or CRO Personnel. Find out more: The Investigational New Drug Framework.
Certified Regulatory Affairs Professional (CRAP) (Applicable for USA)
Price: $799.00
Comprehensive certification covering the global pharmaceutical regulatory landscape with a strong focus on the US FDA and ICH requirements. Provides foundational and advanced strategic capabilities across all major application types.
This certification is for Regulatory Affairs Professionals, Clinical Development Teams, CMC Specialists, and Project Managers. Enroll here: Certified Regulatory Affairs Professional.
Who Needs FDA Regulatory Training?
If you work in any of these roles, regulatory training is mandatory. Regulatory Affairs Associates, Managers, Directors, and Strategy Specialists need to stay current. Pharmaceutical R&D professionals including Formulation Scientists, CMC Specialists, and Clinical Pharmacologists require this training. Quality Assurance and Control professionals such as QA/QC Managers, Compliance Specialists, and Auditors must maintain documented training. Clinical Operations staff including Clinical Research Associates, Clinical Trial Monitors, and Data Managers need regulatory knowledge. Professionals in the Generic Drug Industry working on ANDA submissions, bioequivalence studies, and patent litigation require specialized training. And professionals in the Biotech Industry involved in BLA submissions for biologics, gene therapies, and biosimilars need comprehensive regulatory education.
Frequently Asked Questions
Is online regulatory training accepted by the FDA?
The FDA does not pre-approve training providers, but they do expect that personnel are adequately trained. Our 21 CFR Part 11 compliant certificates provide verifiable, auditable proof of training that is widely accepted during FDA inspections.
What is the record retention requirement for FDA submissions?
Under 21 CFR Part 314 and 312, records must be retained for specific periods, often for two years after approval or for the duration of the investigation. Our certificates provide permanent, traceable records.
Do you offer group discounts for US companies?
Yes. We offer corporate and group enrollment options for teams of all sizes. Contact us for a custom quote.
How long do I have access to the course?
All courses include lifetime access, so you can study at your own pace on your own schedule.
Are the certificates verifiable?
Yes. Each certificate includes a unique verifiable ID that can be checked at gxptrainings.com/verify-certificate/.
Ready to Advance Your Regulatory Career?
Do not wait until an FDA inspection is on the horizon. Invest in your regulatory expertise today. With our self-paced online courses, you can build the knowledge and credentials you need while maintaining your current work schedule. Visit GxP Trainings to explore all our regulatory affairs training courses and take the next step in your professional development.
Authors
